Acoustics as a Metric of Airway Pressure in Premature Infants Using Bubble Continuous Positive Airway Pressure
Launched by MCGILL UNIVERSITY HEALTH CENTRE/RESEARCH INSTITUTE OF THE MCGILL UNIVERSITY HEALTH CENTRE · Jul 2, 2025
Trial Information
Current as of July 24, 2025
Recruiting
Keywords
ClinConnect Summary
This study is looking at how the sounds made by bubble continuous positive airway pressure (bubble CPAP) machines relate to the pressure they deliver to the lungs of premature babies. Bubble CPAP is a common breathing support used for preterm infants, and it works by gently pushing air into their lungs to help them breathe. The researchers want to understand if the bubbling sounds from the machine can help measure and predict how much pressure is actually reaching the baby’s lungs.
The study is open to babies born before 32 weeks of pregnancy who are currently using bubble CPAP with small tubes in their noses. Babies must be at least one week old and still in the hospital’s neonatal intensive care unit to join. If a baby joins the study, the medical team will listen to and record the bubbling sounds while the baby is on bubble CPAP to see how these sounds match the pressure being delivered. This study does not involve any changes to the baby’s care and will help doctors find easier ways to monitor breathing support in tiny infants.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Infants on bCPAP with gestational age \< 32+0 weeks
- • Postmenstrual age between 28+0 and 36+6 weeks at the time of the study
- • Postnatal age greater than 168 hours (7 days) at the time of the study
- • On the bubble CPAP device with binasal prongs at the time of the study
- • Receiving bubble CPAP levels of 5 to 7 cm H2O with gas flows between 6L/min and 10L/min at the time of the study
- Exclusion Criteria:
- • Infants with known major congenital anomalies
- • Infants with known congenital heart disorders
- • Infants with known neuromuscular disease
- • Infants receiving ventilator-derived CPAP at the time of the study
- • Infants receiving CPAP via a nasal mask interface at the time of the study
- • Infants receiving inotropes, narcotics or sedative agents at the time of the study
- • Infants deemed clinically unstable for the study by the attending neonatologist
About Mcgill University Health Centre/Research Institute Of The Mcgill University Health Centre
The McGill University Health Centre (MUHC) and the Research Institute of the McGill University Health Centre (RI-MUHC) are leading institutions in clinical research and healthcare innovation. With a commitment to advancing medical knowledge and improving patient outcomes, the MUHC integrates cutting-edge research with high-quality patient care. The RI-MUHC fosters a collaborative environment where multidisciplinary teams engage in transformative research across various fields, including oncology, neurology, and cardiovascular health. By leveraging state-of-the-art facilities and a robust network of clinical expertise, both entities strive to translate scientific discoveries into effective treatments, ultimately enhancing the quality of life for patients locally and globally.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Montreal, Quebec, Canada
Patients applied
Trial Officials
Wissam Shalish, MD PhD
Principal Investigator
McGill University Health Centre/Research Institute of the McGill University Health Centre
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported